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A B S T R A C T
Undifferentiated pleomorphic sarcoma (UPS), previously known as malignant ﬁbrous histiocytoma, is a
neoplasm that occurs most often in the extremities, trunk, and retroperitoneum. Rarely, UPS can occur in
the cardiac chambers and great vessels. The diagnosis of UPS is difﬁcult to establish with noninvasive
imaging techniques, and these tumors may be mistaken for benign neoplasms preoperatively. Surgical
excision is the standard therapy, although the extent and location of the tumor may limit the ability to
perform a complete resection. Adjuvant chemotherapy and/or radiation are often used for incomplete
resections.
We report the case of a 57-year-old woman with a large right ventricular UPS who presented with signs
of right-sided heart failure. Preoperative imaging was suggestive of a myxoma; however, histopathologic
evaluation of the specimen conﬁrmed a diagnosis of UPS. Microscopic margins of the specimen were
positive, and adjuvant chemotherapy was given. We discuss diagnostic and treatment considerations for
this unusual cardiac tumor.
<Learning objective: The diagnosis and treatment of primary cardiac tumors are challenging.
Noninvasive imaging often lacks the sensitivity and speciﬁcity to differentiate between benign and
malignant neoplasms. In addition, the extent and location of tumor involvement may limit the ability to
perform a complete resection. The diagnosis and treatment of right ventricular undifferentiated
pleomorphic sarcoma are discussed.>
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Primary cardiac tumors are rare, with an autopsy incidence of
0.001–0.030% [1]. Of these, approximately 25% are malignant, with
sarcomas comprising the majority of this group [2]. Distribution
among the cardiac chambers varies, but those arising from the atria
are more common. We report the case of a 57-year-old woman with
a large right ventricular undifferentiated pleomorphic sarcoma that
was thought to be a myxoma on preoperative imaging.
Case report
A 57-year-old woman presented with several weeks of dyspnea,
lower extremity edema, fatigue, and inﬂuenza-like symptoms.
Transaminases were mildly elevated (aspartate transaminase* Corresponding author at: NYU-Langone Medical Center, Suite 9-V, 530 First
Avenue, New York, NY 10016, USA. Tel.: +1 212 263 7835; fax: +1 212 263 2042.
E-mail address: leora.balsam@nyumc.org (L.B. Balsam).
http://dx.doi.org/10.1016/j.jccase.2015.10.008
1878-5409/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All right50 U/L, alanine transaminase 46 U/L) and B-type natriuretic
peptide level was 219.2 pg/mL (normal range 0–100 pg/mL).
Transthoracic echocardiography demonstrated a mass ﬁlling the
right ventricular cavity (Supplementary Fig. 1). Cardiac magnetic
resonance imaging (MRI) showed a 4.9 cm  3.2 cm  5.5 cm
lobulated, somewhat mobile, heterogenous and moderately
enhancing mass that obstructed tricuspid inﬂow (Fig. 1). There
was a broad attachment to the basal inferior right ventricular wall
without evidence of invasion. The mass appeared to be most
consistent with myxoma. Chest and abdominal computed tomog-
raphy failed to show evidence of malignancy elsewhere. Coronary
angiography showed nonobstructive coronary disease and a tumor
blush from distal branches of the right coronary artery.
Surgical excision was performed via median sternotomy with
cardiopulmonary bypass and cardioplegic arrest. The right
ventricular mass was excised through a right atriotomy; surgical
margins of excision included part of the tricuspid subvalvular
apparatus and partial-thickness resection of the right ventricular
wall (Fig. 2). The tricuspid valve was replaced with a 31 mm
bioprosthesis.s reserved.
Fig. 1.
Cardiac magnetic resonance imaging demonstrates right ventricular mass (labeled * in images). (A and B) Two-chamber view at end-diastole and end-systole,
respectively. The right ventricular mass ﬁlls the cavity. It has a broad attachment to the inferior wall of the ventricle without gross invasion. There is no
attachment to the proximal right ventricular outﬂow tract. The mass pushes against the tricuspid valve in systole. (C) Two-chamber ﬁrst-pass perfusion image
demonstrates an enhancing mass adjacent to inferior wall. (D) Four-chamber late gadolinium enhancement image shows enhancing mass. There is lack of
involvement of septum and lateral wall.
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arranged haphazardly in a variable collagenous stroma (Fig. 3)
with negative stains for cytokeratin AE1/AE3, epithelial membrane
antigen (EMA), myogenin, S100, and desmin, CD31, and smooth
muscle actin. There were pleomorphic bizarre cells and no areas of
myxoid change; a vague storiform area was noted. The prolifera-
tion index (Ki-67) was 60%. A diagnosis of high-grade undifferen-
tiated pleomorphic sarcoma was made. The microscopic margins
of the specimen were positive.
The patient’s postoperative hospital course was uneventful and
she was discharged home on postoperative day six. She was
treated with adjuvant chemotherapy (doxorubicin, ifosfamide, and
mesna) as an outpatient. Doxorubicin 75 mg/m2 was given in
divided doses over 3 days and then repeated every three weeks.
Ifosfamide was given 10 g/m2 in divided doses over four days and
then repeated every three weeks. Mesna 500 mg/m2 was given
prior to each ifosfamide dose and then 4 and 8 h after each dose.
The patient completed 2 cycles of chemotherapy but due to
intolerance of side effects, she declined further cycles. The patient
is alive at 14 months without evidence of disease on surveillance
imaging.
Discussion
The term undifferentiated pleomorphic sarcoma (UPS) is used
interchangeably with malignant ﬁbrous histiocytoma (MFH) to
describe tumors with no deﬁnable line of cellular differentiation
and microscopic features of ﬁbroblasts and/or myoﬁbroblastsFig. 2.
Operative images of right ventricular mass. (A) The mass is approached thr
attachment site to the inferior wall of the right ventricle is labeled with bla[3]. The existence of MFH as a distinct entity has been called into
question, and UPS has largely supplanted MFH in the classiﬁcation
of these high-grade tumors. Pathologically there is a lack of
consistent immunoreactivity, so the role of immunohistochemis-
try is in the exclusion of other subtypes of pleomorphic tumors.
Similarly, cytogenetic and molecular genetic aberrations are
generally nonspeciﬁc. UPS most commonly affects the extremities,
followed by the trunk and retroperitoneum.
Although transthoracic and transesophageal echocardiography
are often employed in screening for cardiac masses, their limited
ability to characterize tissue type and distinguish tumors restricts
their diagnostic application. Cardiac MRI can provide more
information regarding the nature of cardiac masses, although no
single imaging feature is pathognomic for malignancy [4,5]. Dy-
namic gadolinium enhancement suggests a highly vascularized
malignancy such as angiosarcoma. Other non-invasive imaging
features that are suggestive of malignancy include ill-deﬁned
margins, size > 5 cm, tissue heterogeneity, broad attachment site,
and right-sided tumors.
In conjunction with cross-sectional imaging, 2-deoxy-2[F-
18]ﬂuoro-D-glucose positron emission tomography (18FDG-PET)
can be utilized to improve preoperative diagnosis of primary
cardiac tumors [6]. In 24 consecutive patients, maximum
standardized uptake values (SUV) were signiﬁcantly higher in
patients with primary malignant lesions versus benign lesions
(8.0  2.1 vs. 2.8  0.6). Further, with selection of a high maximum
SUV threshold of 3.5 (due to increased background myocardial
uptake) a sensitivity of 100% and speciﬁcity of 86% was achieved.ough the right atrium and delivered through the tricuspid valve. (B) The broad
ck arrows. (C) Excised right ventricular mass M, mass.
Fig. 3.
Histologic characteristics of right ventricular high grade undifferentiated pleomorphic sarcoma. (A) Spindle cells are arranged haphazardly in a variably
collagenized stroma (hematoxylin and eosin stain, 100). (B) Hyperchromatic, multinucleated, and bizarre cells with background patchy inﬂammation
(hematoxylin and eosin stain, 400).
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disease, which may alter initial management decisions.
UPS of the right ventricle is a particularly rare entity, with only a
dozen cases reported in the literature. As with other cardiac
sarcomas, prognosis is worse than extra-cardiac tumors with
similar features. The treatment of choice, whenever possible, is
complete resection, and prognosis is signiﬁcantly affected by
completeness of resection. Li et al. recently reported outcomes
following surgical resection of primary cardiac sarcomas [7]. The
median survival was 58 months following complete resection
versus 11 months following incomplete resection. Moreover, the
median local recurrence-free survival in this cohort was 36 months
versus 6 months for complete and incomplete resections,
respectively. Complete resection is difﬁcult to achieve for cardiac
sarcomas, highlighted by a 13% complete resection rate in the
largest contemporary series [2]. Poor rates of complete resection
have been partially attributed to preoperative misdiagnoses.
The role of adjuvant radiation and/or chemotherapy for primary
cardiac sarcomas is not well established, and there is currently no
consensus on the ideal timing and duration of therapy. A large
meta-analysis of adjuvant chemotherapy in resectable extremity
soft tissue sarcomas demonstrated improved overall survival and
freedom from local and distant recurrences (Sarcoma Meta-
analysis Collaboration), yet these ﬁndings were contradicted by a
recent randomized controlled study (EORTC 62931) of high-dose
chemotherapy in a similar cohort [8,9]. A recent retrospective
series spanning 25 years at the Cleveland Clinic found a survival
advantage for patients with primary cardiac sarcoma that received
multimodality treatment (any combination of surgery, radiation
therapy, and chemotherapy) versus those treated with surgery,
radiation therapy, or chemotherapy alone [10].
In cases where complete resection is not possible, cardiac
transplantation has been utilized with variable results. In one
series of 124 patients, ﬁve underwent heart transplantation when a
conservative surgical approach yielded marginal resection, with a
median survival of 27.5 months [2]. Overall, enthusiasm for heart
transplantation is tempered by the scarcity of donor organs and the
unknown interplay between tumor growth and post-transplant
immunomodulatory therapy. More importantly, many patients arenot candidates for heart transplantation due to medical and
psychosocial exclusions, and therefore standard surgical excision
with or without adjuvant chemotherapy remains the standard
treatment for this disease.
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Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.jccase.2015.10.008.
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